Premium
Cardiac metabolism in patients with dilated and hypertrophic cardio‐myopathy: Assessment with proton‐decoupled P‐31 MR spectroscopy
Author(s) -
De Roos Albert,
Doornbos Joost,
Luyten Peter R.,
Oosterwaal Lambère J. M. P.,
den Hollander Jan A.,
van der Wall Ernst E.
Publication year - 1992
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.1880020616
Subject(s) - phosphocreatine , hypertrophic cardiomyopathy , dilated cardiomyopathy , medicine , cardiology , heart failure , energy metabolism
Proton‐decoupled phosphorus‐31 heart spectros‐copy was performed in healthy subjects (n = 9) and patients with dilated cardiomyopathy (DCM, n = 9) or hypertrophic cardiomyopathy (HCM, n = 8). The phosphocreatine (PCr)‐to–adenosine triphosphate ratio (± one standard deviation) after correction for blood contribution and partial saturation was significantly lower in HCM patients relative to the control subjects (1.32 ± 0.29 vs 1.65 ± 0.26, P < .05) but not in DCM patients (1.52 ± 0.58 vs 1.65 ± 0.26). The inorganic phosphate (Pi) peak was resolved only in patients with the highest spectral quality. Myocardial pH was lower in HCM patients (n = 6) relative to control subjects (n = 4) (7.07 ± 0.07 vs 7.15 ± 0.03, P < .05). The Pi/PCr ratio was higher in DCM (n = 3) and HCM (n = 6) patients relative to control subjects (n = 4) (0.29 ± 0.06 and 0.20 ± 0.04, respectively, vs 0.14 ± 0.06; P < .05). Elevated phosphodiester signal in DCM patients correlated with 2,3‐diphosphoglycerate signal (r = .94), reflecting blood pool contamination. P‐31 spectroscopy enabled detection of abnormalities in cardiac metabolism and determination of pH in patients with HCM and DCM.